Week 70 Review

The biggest disaster this week was a heavily discounted placing by RED:RedT Energy causing a 45% drop in share price and obliterating all my potential profits. That absolutely hammered the paper performance in what would have been an OK week otherwise. The only other double digit loser was KIBO:Kibo Mining which dropped 10% and is sadly not sticking around the 7p mark like I'd hoped, but drifting back towards it's historic 5p level.Some news of when shareholders will qualify for the free Katoro Mining shares would be nice.

My latest acquisition NANO:Nanoco Group had a good start, climbing 10% in the few days since I bought them. Time will tell whether I had a rare attack of good timing on this one.

BLUR:Blur Group is in the list of double digit risers again this week, with a new investor building an ever increasing stake. What did look like a basket case a few months ago may now revive, although with my initial investment only being £109 it will never make me very much.

TRX:Tissue Regenix also rose 11% this week, and with the prospect of many big orders coming in, this one has great promise.

Share of the Week is one of my favourites, AMYT:Amryt Pharma. It climbed 17% after news that the company will sell a drug developed by an American company under licence in Europe. As every penny this goes up is worth £272, this increase went some way to make up for the RedT horror.

Here's the performance of the ISA and Share accounts

			Weekly Change
Portfolio cost	£41,739.40		+£404.52
Portfolio sell value (bid price - commission)	£35,750.59	(-14.3%)	-£212.34
Potential profits	£1,493.34		-£263.11
Yr 2 Dividends	£211.79		+£0
Yr 2 Profit from sales	£2,742.86		+£404.12
Yr 2 Average monthly cash profit	£707.69		+£61.38
Yr 2 Avg annual % of current portfolio cost	20.3%
Total Dividends	£879.72		+£0
Total Profit from sales	£6,583.12		+£404.12
Average monthly cash profit	£457.32		+£18.75
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	13.1%

The portfolio cost went up as a result of selling CRL:Creightons and re-investing the profits in NANO:Nanoco. With that in mind, the fact potential profits only fell £263 means it would have been a positive week without the sale. The £404 profit did the world of good for my performance, lifting overall performance by £18.75 a month and giving me a bit of a buffer for when AFPO:African Potash de-lists.

Still looking pretty dreadful. The key reason has been the dramatic drops in OPTI:Optibiotix, RED:RedT Energy, CWR:Ceres Power, CMCL:Caledonia Mining and TLOU:Tlou Energy. These have all been somewhat unexpected, but I believe they are also short term. If these can turn around, then the deficit could narrow quite quickly.


The SIPP looks like this after week 54

			Weekly Change
Portfolio cost	£15,716.08		+£0
Portfolio sell value (bid price - commission)	£17,790.36	(+13.2%)	-£21.06
Potential profits	£2,641.43		-£331.40
Yr 2 Dividends	£0		+£0
Yr 2 Profit from sales	£0		+£0
Yr 2 Average monthly cash profit	£0		+£0
Yr 2 Avg annual % of current portfolio cost	0%
Total Dividends	£413.19		+£0
Total Profit from sales	£2,349.86		+£0
Average monthly cash profit	£217.12		-£4.10
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	16.6%

Potential profits hammered by the RED:RedT placing and the decline of CWR:Ceres Power, although ALM:Allied Minds is just about profitable again which reduced the losses, and CAML:Central Asia Metals had another good week and is responsible for over half the total paper profit.

I've added stats for year 2, but with no dividends or sales it will take a while before there's anything to report.

The Trading account looks the same as usual

			Weekly Change
Portfolio cost	£499.95		+£0
Cash	£0.05		+£0
Portfolio sell value (bid price - commission)	£390.95	(-21.8%)	+£0
Potential profits	£0		+£0
Dividends	£0		+£0
Profit from sales	£0		+£0
Average monthly cash profit	£0		+£0
(Sold stocks profit + Dividends - Fees / Months)
Avg annual % of current portfolio cost	0%

Yuck!

That's it for another week. The combined portfolios are £4,000 in the red on paper, which is pretty bad, especially given that the SIPP is over £2,000 in profit - confirming my other accounts are at their worst ever paper losses. However, there is much hope for a turnaround, and with the actual profits from sales and dividends at a combined level of over £670 a month, I'm still very happy with how things are going. All it takes is one bit of good news from OPTI:Optibiotix and continued interest in AMYT:Amryt Pharma, and the graphs will start to look much, much better.